Skip to Content

Drug interactions between Soliqua and Xultophy

Results for the following 2 drugs:
Soliqua (insulin glargine/lixisenatide)
Xultophy (insulin degludec/liraglutide)

Interactions between your drugs

Moderate

insulin glargine ↔ liraglutide

Applies to:Soliqua (insulin glargine/lixisenatide) and Xultophy (insulin degludec/liraglutide)

Using liraglutide together with insulin glargine can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

insulin degludec ↔ lixisenatide

Applies to:Xultophy (insulin degludec/liraglutide) and Soliqua (insulin glargine/lixisenatide)

Using lixisenatide together with insulin degludec can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

liraglutide food

Applies to: Xultophy (insulin degludec / liraglutide)

Liraglutide may affect the absorption of other medications that you take by mouth. In some cases, this may affect how well and/or how fast those medications work, or it may make no difference. Talk to a healthcare provider if you have any questions or concerns, and contact your doctor if your symptoms worsen or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

lixisenatide food

Applies to: Soliqua (insulin glargine / lixisenatide)

Lixisenatide may affect the absorption of other medications that you take by mouth. In some cases, this may affect how well and/or how fast those medications work, or it may make no difference. Talk to a healthcare provider if you have any questions or concerns, and contact your doctor if your symptoms worsen or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Intermediate- and long-acting insulins

Therapeutic duplication

The recommended maximum number of medicines in the 'intermediate- and long-acting insulins' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'intermediate- and long-acting insulins' category:

  • insulin glargine (active ingredient in Soliqua (insulin glargine/lixisenatide))
  • insulin degludec (active ingredient in Xultophy (insulin degludec/liraglutide))

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Duplication

Incretin-based therapies

Therapeutic duplication

The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'incretin-based therapies' category:

  • lixisenatide (active ingredient in Soliqua (insulin glargine/lixisenatide))
  • liraglutide (active ingredient in Xultophy (insulin degludec/liraglutide))

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide